Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
3,769
archived clinical trials in
Migraine Headaches

To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated:  12/31/1969
Regional Clinical Research, Inc.
2264
mi
from 98109
Endwell, NY
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated: 12/31/1969
Regional Clinical Research, Inc.
2264
mi
from 98109
Endwell, NY
Click here to add this to my saved trials
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated:  12/31/1969
Central New York Clinical Research
2240
mi
from 98109
Manlius, NY
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated: 12/31/1969
Central New York Clinical Research
2240
mi
from 98109
Manlius, NY
Click here to add this to my saved trials
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated:  12/31/1969
Clinilabs Inc.
2401
mi
from 98109
New York, NY
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated: 12/31/1969
Clinilabs Inc.
2401
mi
from 98109
New York, NY
Click here to add this to my saved trials
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated:  12/31/1969
Rochester Clinical Research Inc.
2160
mi
from 98109
Rochester, NY
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated: 12/31/1969
Rochester Clinical Research Inc.
2160
mi
from 98109
Rochester, NY
Click here to add this to my saved trials
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated:  12/31/1969
Upstate Clinical Research Associates
2114
mi
from 98109
Williamsville, NY
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated: 12/31/1969
Upstate Clinical Research Associates
2114
mi
from 98109
Williamsville, NY
Click here to add this to my saved trials
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated:  12/31/1969
Plains Medical Clinic
1194
mi
from 98109
Fargo, ND
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated: 12/31/1969
Plains Medical Clinic
1194
mi
from 98109
Fargo, ND
Click here to add this to my saved trials
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated:  12/31/1969
Radiant Akron
mi
from 98109
Akron, OH
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated: 12/31/1969
Radiant Akron
mi
from 98109
Akron, OH
Click here to add this to my saved trials
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated:  12/31/1969
Radiant Research - Cincinnati
1967
mi
from 98109
Cincinnati, OH
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated: 12/31/1969
Radiant Research - Cincinnati
1967
mi
from 98109
Cincinnati, OH
Click here to add this to my saved trials
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated:  12/31/1969
Rapid Medical Research, Inc.
2029
mi
from 98109
Cleveland, OH
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated: 12/31/1969
Rapid Medical Research, Inc.
2029
mi
from 98109
Cleveland, OH
Click here to add this to my saved trials
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated:  12/31/1969
Ohio Clinical Research
2029
mi
from 98109
Lyndhurst, OH
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated: 12/31/1969
Ohio Clinical Research
2029
mi
from 98109
Lyndhurst, OH
Click here to add this to my saved trials
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated:  12/31/1969
IPS Research Company
1522
mi
from 98109
Oklahoma City, OK
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated: 12/31/1969
IPS Research Company
1522
mi
from 98109
Oklahoma City, OK
Click here to add this to my saved trials
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated:  12/31/1969
Lynn Health Science Institute
1523
mi
from 98109
Oklahoma City, OK
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated: 12/31/1969
Lynn Health Science Institute
1523
mi
from 98109
Oklahoma City, OK
Click here to add this to my saved trials
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated:  12/31/1969
Summit Research Network
146
mi
from 98109
Portland, OR
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated: 12/31/1969
Summit Research Network
146
mi
from 98109
Portland, OR
Click here to add this to my saved trials
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated:  12/31/1969
Oregon Center for Clinical Investigations, Inc
188
mi
from 98109
Salem, OR
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated: 12/31/1969
Oregon Center for Clinical Investigations, Inc
188
mi
from 98109
Salem, OR
Click here to add this to my saved trials
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated:  12/31/1969
Lehigh Center for Clinical Research
2335
mi
from 98109
Allentown, PA
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated: 12/31/1969
Lehigh Center for Clinical Research
2335
mi
from 98109
Allentown, PA
Click here to add this to my saved trials
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated:  12/31/1969
Suburban Research Associates
2363
mi
from 98109
Media, PA
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated: 12/31/1969
Suburban Research Associates
2363
mi
from 98109
Media, PA
Click here to add this to my saved trials
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated:  12/31/1969
Clinical Research of Philadelphia LLC
2377
mi
from 98109
Philadelphia, PA
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated: 12/31/1969
Clinical Research of Philadelphia LLC
2377
mi
from 98109
Philadelphia, PA
Click here to add this to my saved trials
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated:  12/31/1969
Frontier Clinical Research, LLC
2164
mi
from 98109
Scottdale, PA
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated: 12/31/1969
Frontier Clinical Research, LLC
2164
mi
from 98109
Scottdale, PA
Click here to add this to my saved trials
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated:  12/31/1969
Frontier Clinical Research, LLC
2162
mi
from 98109
Smithfield, PA
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated: 12/31/1969
Frontier Clinical Research, LLC
2162
mi
from 98109
Smithfield, PA
Click here to add this to my saved trials
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated:  12/31/1969
Radiant Research, Inc.
2227
mi
from 98109
Anderson, SC
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated: 12/31/1969
Radiant Research, Inc.
2227
mi
from 98109
Anderson, SC
Click here to add this to my saved trials
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated:  12/31/1969
Coastal Carolina Research Center
2425
mi
from 98109
Mount Pleasant, SC
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated: 12/31/1969
Coastal Carolina Research Center
2425
mi
from 98109
Mount Pleasant, SC
Click here to add this to my saved trials
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated:  12/31/1969
Meridian Clinical Research
1304
mi
from 98109
Dakota Dunes, SD
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated: 12/31/1969
Meridian Clinical Research
1304
mi
from 98109
Dakota Dunes, SD
Click here to add this to my saved trials
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated:  12/31/1969
Volunteer Research Group
2113
mi
from 98109
Knoxville, TN
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated: 12/31/1969
Volunteer Research Group
2113
mi
from 98109
Knoxville, TN
Click here to add this to my saved trials
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated:  12/31/1969
CNS Healthcare of Memphis
1876
mi
from 98109
Memphis, TN
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated: 12/31/1969
CNS Healthcare of Memphis
1876
mi
from 98109
Memphis, TN
Click here to add this to my saved trials
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated:  12/31/1969
Trinity Clinical Research
2029
mi
from 98109
Tullahoma, TN
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated: 12/31/1969
Trinity Clinical Research
2029
mi
from 98109
Tullahoma, TN
Click here to add this to my saved trials
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated:  12/31/1969
Tekton Research
1770
mi
from 98109
Austin, TX
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated: 12/31/1969
Tekton Research
1770
mi
from 98109
Austin, TX
Click here to add this to my saved trials
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated:  12/31/1969
DiscoveResearch, Inc.
1806
mi
from 98109
Bryan, TX
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated: 12/31/1969
DiscoveResearch, Inc.
1806
mi
from 98109
Bryan, TX
Click here to add this to my saved trials
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated:  12/31/1969
FutureSearch Trials
1678
mi
from 98109
Dallas, TX
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated: 12/31/1969
FutureSearch Trials
1678
mi
from 98109
Dallas, TX
Click here to add this to my saved trials
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated:  12/31/1969
Earle Research
1911
mi
from 98109
Houston, TX
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated: 12/31/1969
Earle Research
1911
mi
from 98109
Houston, TX
Click here to add this to my saved trials
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated:  12/31/1969
Research Trials Worldwide LLC
1882
mi
from 98109
Humble, TX
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated: 12/31/1969
Research Trials Worldwide LLC
1882
mi
from 98109
Humble, TX
Click here to add this to my saved trials
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated:  12/31/1969
Radiant Research - San Antonio
1779
mi
from 98109
San Antonio, TX
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated: 12/31/1969
Radiant Research - San Antonio
1779
mi
from 98109
San Antonio, TX
Click here to add this to my saved trials
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated:  12/31/1969
ClinPoint Trials, LLC
1698
mi
from 98109
Waxahachie, TX
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated: 12/31/1969
ClinPoint Trials, LLC
1698
mi
from 98109
Waxahachie, TX
Click here to add this to my saved trials
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated:  12/31/1969
Foothill Family Draper Clinic
mi
from 98109
Draper, UT
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated: 12/31/1969
Foothill Family Draper Clinic
mi
from 98109
Draper, UT
Click here to add this to my saved trials
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated:  12/31/1969
Advanced Research Institute
678
mi
from 98109
Ogden, UT
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated: 12/31/1969
Advanced Research Institute
678
mi
from 98109
Ogden, UT
Click here to add this to my saved trials
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated:  12/31/1969
Advanced Clinical Research, Inc.
707
mi
from 98109
West Jordan, UT
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated: 12/31/1969
Advanced Clinical Research, Inc.
707
mi
from 98109
West Jordan, UT
Click here to add this to my saved trials
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated:  12/31/1969
Charlottesville Medical Research Inc.
2286
mi
from 98109
Charlottesville, VA
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated: 12/31/1969
Charlottesville Medical Research Inc.
2286
mi
from 98109
Charlottesville, VA
Click here to add this to my saved trials
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated:  12/31/1969
Clinical Research Associates of Tidewater
2429
mi
from 98109
Norfolk, VA
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Associates of Tidewater
2429
mi
from 98109
Norfolk, VA
Click here to add this to my saved trials
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated:  12/31/1969
Tidewater Integrated Medical Research
2443
mi
from 98109
Virginia Beach, VA
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated: 12/31/1969
Tidewater Integrated Medical Research
2443
mi
from 98109
Virginia Beach, VA
Click here to add this to my saved trials
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated:  12/31/1969
Northwest Clinical Research Center
9
mi
from 98109
Bellevue, WA
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated: 12/31/1969
Northwest Clinical Research Center
9
mi
from 98109
Bellevue, WA
Click here to add this to my saved trials
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated:  12/31/1969
North Seattle Womens Group
3
mi
from 98109
Seattle, WA
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated: 12/31/1969
North Seattle Womens Group
3
mi
from 98109
Seattle, WA
Click here to add this to my saved trials
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated:  12/31/1969
SSM Dean Health Research
mi
from 98109
Madison, WI
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated: 12/31/1969
SSM Dean Health Research
mi
from 98109
Madison, WI
Click here to add this to my saved trials
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated:  12/31/1969
FutureSearch Trials of Neurology
1768
mi
from 98109
Austin, TX
To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine.
Status: Enrolling
Updated: 12/31/1969
FutureSearch Trials of Neurology
1768
mi
from 98109
Austin, TX
Click here to add this to my saved trials
Pharmacokinetics (PK), Safety, and Tolerability of M207 at Two App Sites With Intranasal Zolmitriptan 2.5 mg in Healthy Volunteers
A Randomized Open-label Four-way Crossover Study to Compare the PK, Safety, and Tolerability of M207 3.8 mg (Administered as Two 1.9 mg Patches) at Two Different Application Locations (Upper Arm and Thigh) for 30 Minutes With Intranasal Zolmitriptan 2.5 mg and 1 Hour Wear Time (Upper Arm) in Healthy Volunteers
Status: Enrolling
Updated:  12/31/1969
Hill Top Research, Inc.
mi
from 98109
Neptune, NJ
Pharmacokinetics (PK), Safety, and Tolerability of M207 at Two App Sites With Intranasal Zolmitriptan 2.5 mg in Healthy Volunteers
A Randomized Open-label Four-way Crossover Study to Compare the PK, Safety, and Tolerability of M207 3.8 mg (Administered as Two 1.9 mg Patches) at Two Different Application Locations (Upper Arm and Thigh) for 30 Minutes With Intranasal Zolmitriptan 2.5 mg and 1 Hour Wear Time (Upper Arm) in Healthy Volunteers
Status: Enrolling
Updated: 12/31/1969
Hill Top Research, Inc.
mi
from 98109
Neptune, NJ
Click here to add this to my saved trials
Headache in the Emergency Department (ED) - A Multi-Center Research Network to Optimize the ED Treatment of Migraines
Parenteral Corticosteroids as Adjuvant Therapy for Migraine Headaches
Status: Enrolling
Updated:  12/31/1969
Jacobi Medical Center
2405
mi
from 98109
Bronx, NY
Headache in the Emergency Department (ED) - A Multi-Center Research Network to Optimize the ED Treatment of Migraines
Parenteral Corticosteroids as Adjuvant Therapy for Migraine Headaches
Status: Enrolling
Updated: 12/31/1969
Jacobi Medical Center
2405
mi
from 98109
Bronx, NY
Click here to add this to my saved trials
Headache in the Emergency Department (ED) - A Multi-Center Research Network to Optimize the ED Treatment of Migraines
Parenteral Corticosteroids as Adjuvant Therapy for Migraine Headaches
Status: Enrolling
Updated:  12/31/1969
Columbia University Medical Center
2400
mi
from 98109
Manhattan, NY
Headache in the Emergency Department (ED) - A Multi-Center Research Network to Optimize the ED Treatment of Migraines
Parenteral Corticosteroids as Adjuvant Therapy for Migraine Headaches
Status: Enrolling
Updated: 12/31/1969
Columbia University Medical Center
2400
mi
from 98109
Manhattan, NY
Click here to add this to my saved trials
Headache in the Emergency Department (ED) - A Multi-Center Research Network to Optimize the ED Treatment of Migraines
Parenteral Corticosteroids as Adjuvant Therapy for Migraine Headaches
Status: Enrolling
Updated:  12/31/1969
St. Luke's Hospital
2401
mi
from 98109
New York, NY
Headache in the Emergency Department (ED) - A Multi-Center Research Network to Optimize the ED Treatment of Migraines
Parenteral Corticosteroids as Adjuvant Therapy for Migraine Headaches
Status: Enrolling
Updated: 12/31/1969
St. Luke's Hospital
2401
mi
from 98109
New York, NY
Click here to add this to my saved trials
High School Start Time and Teen Migraine Frequency
High School Start Time and Adolescent Migraine Frequency
Status: Enrolling
Updated:  12/31/1969
University of California at San Francisco (UCSF)
682
mi
from 98109
San Francisco, CA
High School Start Time and Teen Migraine Frequency
High School Start Time and Adolescent Migraine Frequency
Status: Enrolling
Updated: 12/31/1969
University of California at San Francisco (UCSF)
682
mi
from 98109
San Francisco, CA
Click here to add this to my saved trials
Adherence to and Beliefs on Recommendations for Behavioral Treatment for Migraine
Adherence to and Beliefs on Recommendations for Behavioral Treatment for Migraine
Status: Enrolling
Updated:  12/31/1969
NYU Langone
2402
mi
from 98109
New York, NY
Adherence to and Beliefs on Recommendations for Behavioral Treatment for Migraine
Adherence to and Beliefs on Recommendations for Behavioral Treatment for Migraine
Status: Enrolling
Updated: 12/31/1969
NYU Langone
2402
mi
from 98109
New York, NY
Click here to add this to my saved trials
ESCAPE Migraine Trial
Effect of Septal Closure of Atrial PFO on Events of Migraine With Premere: ESCAPE Migraine Trial
Status: Enrolling
Updated:  12/31/1969
Mayo Clinic Hospital
1114
mi
from 98109
Scottsdale, AZ
ESCAPE Migraine Trial
Effect of Septal Closure of Atrial PFO on Events of Migraine With Premere: ESCAPE Migraine Trial
Status: Enrolling
Updated: 12/31/1969
Mayo Clinic Hospital
1114
mi
from 98109
Scottsdale, AZ
Click here to add this to my saved trials
ESCAPE Migraine Trial
Effect of Septal Closure of Atrial PFO on Events of Migraine With Premere: ESCAPE Migraine Trial
Status: Enrolling
Updated:  12/31/1969
Newport Beach Clinical Research Associates, Inc.
995
mi
from 98109
Newport Beach, CA
ESCAPE Migraine Trial
Effect of Septal Closure of Atrial PFO on Events of Migraine With Premere: ESCAPE Migraine Trial
Status: Enrolling
Updated: 12/31/1969
Newport Beach Clinical Research Associates, Inc.
995
mi
from 98109
Newport Beach, CA
Click here to add this to my saved trials